Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Repligen Corporation RGEN
$151.90
-$0.44 (-0.29%)
На 18:00, 12 мая 2023
+25.08%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
8400441600.00000000
-
week52high
262.26
-
week52low
137.21
-
Revenue
801536000
-
P/E TTM
53
-
Beta
1.08269800
-
EPS
3.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 12:30
Описание компании
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 03 авг 2022 г. |
| Stephens & Co. | Overweight | Overweight | 03 авг 2022 г. |
| Keybanc | Overweight | Overweight | 03 авг 2022 г. |
| UBS | Buy | 20 июл 2022 г. | |
| SVB Leerink | Outperform | Outperform | 28 апр 2022 г. |
| RBC Capital | Sector Perform | 07 дек 2022 г. | |
| SVB Leerink | Outperform | Outperform | 06 янв 2023 г. |
| Deutsche Bank | Hold | 14 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hunt Anthony | A | 34246 | 25000 | 11 ноя 2022 г. |
| Hunt Anthony | D | 178265 | 25000 | 11 ноя 2022 г. |
| Hunt Anthony | A | 203265 | 25000 | 11 ноя 2022 г. |
| Snodgres Jon | A | 2108 | 466 | 07 окт 2022 г. |
| Snodgres Jon | A | 34972 | 466 | 07 окт 2022 г. |
| DAWES KAREN A | D | 76401 | 775 | 09 сент 2022 г. |
| Hunt Anthony | A | 59246 | 10000 | 08 сент 2022 г. |
| Hunt Anthony | D | 178265 | 245 | 08 сент 2022 г. |
| Hunt Anthony | D | 178510 | 4873 | 08 сент 2022 г. |
| Hunt Anthony | D | 183383 | 10490 | 08 сент 2022 г. |
Новостная лента
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
Zacks Investment Research
03 мая 2023 г. в 14:27
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
02 мая 2023 г. в 10:40
Repligen (RGEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.92 per share a year ago.
Why Repligen Stock Is Sinking Today
The Motley Fool
25 апр 2023 г. в 14:07
Repligen is set to release its first-quarter earnings next Tuesday. Demand for its COVID-related products is declining, and investors appear to be bracing for the company to miss Wall Street's consensus estimates.
Repligen to Report First Quarter 2023 Financial Results
GlobeNewsWire
18 апр 2023 г. в 07:30
Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET
Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?
Zacks Investment Research
24 мар 2023 г. в 12:59
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?